Novel calcium sensing receptor ligands: a patent survey
Authors:
- 16 March 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (5) , 681-698
Abstract
Introduction: In the parathyroid gland, the calcium sensing receptor responds to small changes in circulating levels of Ca2+, and consequently stimulates or inhibits the secretion of parathyroid hormone (PTH). Thus, ligands potentiating the action of calcium (calcimimetics) lead to decreased PTH secretion and can thus be useful for the treatment of hyperparathyroidism. On the other hand, ligands which antagonize the action of calcium (calcilytics) stimulate PTH secretion, favoring bone tissue regeneration. Areas covered: This review first discusses the rapid development of calcimimetics (only one of which has been approved for the treatment of hyperparathyroidism) followed by that of calcilytics (none of which has as yet been approved for the treatment of osteoporosis). Peer-reviewed articles generated by these patents are also surveyed. Expert opinion: The rapid progress in developing a clinically approved calcimimetic has not been matched by an identical success in finding an orally available calcilytic useful for the treatment of osteoporosis. However, the growing importance of osteoporosis as a debilitating disease is a stimulating factor in discovering such compounds.Keywords
This publication has 59 references indexed in Scilit:
- Presynaptic External Calcium Signaling Involves the Calcium-Sensing Receptor in Neocortical Nerve TerminalsPLOS ONE, 2010
- Novel Role of the Calcium-Sensing Receptor in Blood Pressure ModulationHypertension, 2008
- The expression and function of Ca2+‐sensing receptors in rat mesenteric artery; comparative studies using a model of type II diabetesBritish Journal of Pharmacology, 2008
- Identification and Dissection of Ca2+-binding Sites in the Extracellular Domain of Ca2+-sensing ReceptorJournal of Biological Chemistry, 2007
- Therapeutic Use of CalcimimeticsAnnual Review of Medicine, 2006
- Calcimimetics and calcilytics—fooling the calcium receptorThe Lancet, 2005
- Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2005
- In vitro effects of strontium ranelate on the extracellular calcium-sensing receptorBiochemical and Biophysical Research Communications, 2004
- N1‐Arylsulfonyl‐N2‐(1‐(1‐naphthyl)ethyl)‐1,2‐diaminocyclohexanes: A New Class of Calcilytic Agents Acting at the Calcium‐Sensing ReceptorChemBioChem, 2004
- PTH: A future role in the management of osteoporosis?Journal of Bone and Mineral Research, 1996